Published in Cancer Weekly, October 19th, 2004
Three of the poster presentations involved the humanized anti-CD74 monoclonal antibody conjugated with the anticancer drug, doxorubicin (DOX). The first one evaluated the in vitro efficacy of the drug conjugate on CD74-expressing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.